Difference between revisions of "Nedaplatin (Aqupla)"
m |
m |
||
| Line 11: | Line 11: | ||
*'''Code name:''' 254-S | *'''Code name:''' 254-S | ||
*'''Generic name:''' nedaplat | *'''Generic name:''' nedaplat | ||
| − | *'''Brand name:''' Aqupla | + | *'''Brand name:''' Aqupla, Jiebaishu |
==References== | ==References== | ||
Revision as of 00:59, 25 August 2019
General information
Class/mechanism: A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. [1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Also known as
- Code name: 254-S
- Generic name: nedaplat
- Brand name: Aqupla, Jiebaishu